©The Author(s) 2024.
World J Gastroenterol. Dec 28, 2024; 30(48): 5152-5161
Published online Dec 28, 2024. doi: 10.3748/wjg.v30.i48.5152
Published online Dec 28, 2024. doi: 10.3748/wjg.v30.i48.5152
Table 4 Incidence of adverse drug reactions of the two treatment groups, n (%)
| Variables | Rebamipide/nizatidine (n = 128) | Nizatidine (n = 125) |
| Total | 3 (2.34) | 2 (1.60) |
| Gastrointestinal disorders | 3 (2.34) | 1 (0.80) |
| Diarrhea | 2 (1.56) | 0 |
| Dyspepsia | 0 | 1 (0.80) |
| Epigastric discomfort | 1 (0.78) | 0 |
| Nausea | 1 (0.78) | 0 |
| Immune system disorders | 0 | 1 (0.80) |
| Drug hypersensitivity | 0 | 1 (0.80) |
| Skin and subcutaneous tissue disorders | 0 | 1 (0.80) |
| Yellow skin | 0 | 1 (0.80) |
- Citation: Kang D, Choi MG, Shim KN, Jung HK, Nam SJ, Park JH, Kim SG, Kim NH, Hong SJ, Jeon TJ, Chung JI, Lee HL, Lee JY, Kim TO, Lee CM, Kim SM, Kim JH, Kim JE, Moon JS, Kim HD, Lee WS, Park HJ. Efficacy and safety of rebamipide/nizatidine in patients with erosive gastritis: A randomized, multicenter, phase 4 study. World J Gastroenterol 2024; 30(48): 5152-5161
- URL: https://www.wjgnet.com/1007-9327/full/v30/i48/5152.htm
- DOI: https://dx.doi.org/10.3748/wjg.v30.i48.5152